Zynex (NASDAQ:ZYXI – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $0.20 for the period, compared to the consensus earnings per share estimate of $0.51. The company issued revenue guidance of $200.0 million, compared to the consensus revenue estimate of $226.95 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.
Zynex Trading Down 12.4 %
NASDAQ ZYXI traded down $1.26 during trading on Friday, hitting $8.93. The stock had a trading volume of 1,034,596 shares, compared to its average volume of 195,244. The company has a market capitalization of $283.75 million, a PE ratio of 38.83 and a beta of 0.53. The company has a quick ratio of 2.87, a current ratio of 3.58 and a debt-to-equity ratio of 1.76. The firm has a 50 day moving average price of $9.55 and a 200 day moving average price of $11.06. Zynex has a twelve month low of $6.88 and a twelve month high of $13.77.
Zynex (NASDAQ:ZYXI – Get Free Report) last released its earnings results on Thursday, July 25th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $49.88 million during the quarter, compared to analyst estimates of $51.99 million. Zynex had a net margin of 4.33% and a return on equity of 16.34%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. As a group, equities research analysts forecast that Zynex will post 0.51 earnings per share for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Zynex
About Zynex
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Articles
- Five stocks we like better than Zynex
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Invest in the FAANG Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Business Services Stocks Investing
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.